Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2002 5
2004 1
2005 2
2006 7
2007 3
2008 3
2009 3
2010 6
2011 11
2012 12
2013 9
2014 8
2015 9
2016 10
2017 9
2018 14
2019 20
2020 19
2021 4
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 29594485

131 results

Results by year

Filters applied: . Clear all
Page 1
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients.
Velasco R, Bruna J, Briani C, Argyriou AA, Cavaletti G, Alberti P, Frigeni B, Cacciavillani M, Lonardi S, Cortinovis D, Cazzaniga M, Santos C, Kalofonos HP. Velasco R, et al. J Neurol Neurosurg Psychiatry. 2014 Apr;85(4):392-8. doi: 10.1136/jnnp-2013-305334. Epub 2013 Jun 29. J Neurol Neurosurg Psychiatry. 2014. PMID: 23813745 Clinical Trial.
Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies.
Reddy SM, Vergo MT, Paice JA, Kwon N, Helenowski IB, Benson AB, Mulcahy MF, Nimeiri HS, Harden RN. Reddy SM, et al. Clin Colorectal Cancer. 2016 Mar;15(1):37-46. doi: 10.1016/j.clcc.2015.07.001. Epub 2015 Jul 26. Clin Colorectal Cancer. 2016. PMID: 26337211
Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A, Yamashita K, Tanioka H, Tsuji A, Inukai M, Yamakawa T, Yamatsuji T, Yoshimitsu M, Toyota K, Yamano T, Nagasaka T, Okajima M. Tsuruta A, et al. Drug Des Devel Ther. 2016 Nov 23;10:3827-3835. doi: 10.2147/DDDT.S112322. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27920498 Free PMC article. Clinical Trial.
131 results